Related Experiment Video
Updated: Jan 7, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Screening and application of a coagulation peptide-KFVLK with rapid hemostatic property
Xin Liu1, Zekai Ren1, Xin Ding2
1College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao 266071, China.
Abstract:
Wound hemostasis and healing have been important issues faced in wound therapy. Bioactive peptides are widely used in wound therapy due to their good biocompatibility and tunable functionality. Here we prepared Erythrocyte Membrane Chromatography Packing Material (EMCPM) by combining SiO2 stationary-phase microspheres and cell membranes of erythrocytes through diazotized resin, and screened the coagulation peptide KFVLK from mobile phase peptide libraries, which lyophilized in the form of white solid particles with good biosafety, and could rapidly adsorb erythrocytes and platelets to stop wound bleeding. In the liver hemorrhage model, it could stop wound bleeding within 20 s, which reduced blood loss by 50 % compared with the control group. Meanwhile, it has good performance in promoting wound healing, with a healing rate of 88 % on fibroblasts within 24 h. The wound healing model also verified its performance. In conclusion, this screening method is of great significance for the preparation of coagulation peptides and hemostatic treatment of wounds.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care

